Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine announced FDA clearance of its Investigational New Drug (IND) application for PM577a, an in vivo Prime Editor targeting the H1069Q mutation in the ATP7B gene responsible for Wilson Disease (WD). This clearance enables initiation of a global Phase 1/2 clinical trial, with expected trial start in the second half of 2026 and initial cli…